Cargando…

GASC1-Adapted Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Prospective Clinical Biomarker Trial

Neoadjuvant chemotherapy (NCT) is a standard care for esophageal squamous cell carcinoma (ESCC), but the efficacy is unsatisfactory. Cancer stem cells (CSCs) play key roles in chemotherapy resistance. Gene amplified in squamous cell carcinoma 1 (GASC1) is a neoteric gene in stemness maintaining of E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Ruinuo, Mi, Youjia, Yuan, Xiang, Kong, Dejiu, Li, Wanying, Li, Ruonan, Wang, Bingbing, Zhu, Yafei, Kong, Jinyu, Ma, Zhikun, Li, Na, Mi, Qiangjian, Gao, Shegan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204099/ https://www.ncbi.nlm.nih.gov/pubmed/32411232 http://dx.doi.org/10.1155/2020/1607860

Ejemplares similares

GASC1 Promotes Stemness of Esophageal Squamous Cell Carcinoma via NOTCH1 Promoter Demethylation
por: Jia, Ruinuo, et al.
Publicado: (2019)

Corrigendum to “KDM4C, a H3K9me3 histone demethylase, is involved in the maintenance of human ESCC-initiating cells by epigenetically enhancing SOX2 expression” [Neoplasia 18 (2016) 594-609]
por: Yuan, Xiang, et al.
Publicado: (2016)

KDM4C, a H3K9me3 Histone Demethylase, is Involved in the Maintenance of Human ESCC-Initiating Cells by Epigenetically Enhancing SOX2 Expression()
por: Yuan, Xiang, et al.
Publicado: (2016)

GASC1 promotes glioma progression by enhancing NOTCH1 signaling
por: Xiao, Zhengzheng, et al.
Publicado: (2021)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

Effect of circumferential resection margin status on survival and recurrence in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
por: Gu, Yi-Min, et al.
Publicado: (2022)

GASC1 promotes hepatocellular carcinoma progression by inhibiting the degradation of ROCK2
por: Shao, Na, et al.
Publicado: (2021)

The relationship between Porphyromonas gingivalis and oesophageal squamous cell carcinoma: a literature review
por: Kong, Jinyu, et al.
Publicado: (2023)

Associations of Porphyromonas gingivalis Infection and Low Beclin1 Expression With Clinicopathological Parameters and Survival of Esophageal Squamous Cell Carcinoma Patients
por: Guo, Yibo, et al.
Publicado: (2021)

Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer
por: Liu, Gang, et al.
Publicado: (2009)

A Novel Amplicon at 9p23‐24 in Squamous Cell Carcinoma of the Esophagus That Lies Proximal to GASC1 and Harbors NFIB
por: Yang, Zeng‐Quan, et al.
Publicado: (2001)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
por: Yang, Weixiong, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
por: Zhou, Qing, et al.
Publicado: (2023)

Chemoradiation versus oesophagectomy for locally advanced oesophageal cancer in Chinese patients: study protocol for a randomised controlled trial
por: Jia, Ruinuo, et al.
Publicado: (2019)

Histone demethylase GASC1 - a potential prognostic and predictive marker in invasive breast cancer
por: Berdel, Bozena, et al.
Publicado: (2012)

Directional Migration in Esophageal Squamous Cell Carcinoma (ESCC) is Epigenetically Regulated by SET Nuclear Oncogene, a Member of the Inhibitor of Histone Acetyltransferase Complex()
por: Yuan, Xiang, et al.
Publicado: (2017)

The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy
por: Li, Keting, et al.
Publicado: (2023)

Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer
por: Gao, Shegan, et al.
Publicado: (2016)

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
por: Li, Qing, et al.
Publicado: (2022)

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
por: Zhang, Zhi, et al.
Publicado: (2022)

The prognostic significance of the circumferential resection margin in esophageal squamous cell carcinoma patients without neoadjuvant treatment
por: Yang, Zhaoyang, et al.
Publicado: (2022)

Immune Infiltration Represents Potential Diagnostic and Prognostic Biomarkers for Esophageal Squamous Cell Carcinoma
por: Li, Mengxiang, et al.
Publicado: (2022)

Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
por: Xu, Yaping, et al.
Publicado: (2012)

Neoadjuvant chemoradiotherapy plus surgery in the treatment of potentially resectable thoracic esophageal squamous cell carcinoma
por: Yan, Mao-Hui, et al.
Publicado: (2020)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta‐analysis
por: Fan, Mengying, et al.
Publicado: (2015)

Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
por: Yin, Jun, et al.
Publicado: (2023)

The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
por: He, Wenwu, et al.
Publicado: (2023)

KDM4C (GASC1) lysine demethylase is associated with mitotic chromatin and regulates chromosome segregation during mitosis
por: Kupershmit, Ilana, et al.
Publicado: (2014)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma
por: FUJIWARA, YOSHINORI, et al.
Publicado: (2013)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

Systematic review and meta-analysis of endoscopic ultrasonography in staging diagnosis of esophageal cancer after neoadjuvant radiotherapy and chemotherapy
por: Li, Xiaodong, et al.
Publicado: (2022)

Circulating microRNAs as novel potential diagnostic biomarkers for ovarian cancer: a systematic review and updated meta-analysis
por: Wang, Xinshuai, et al.
Publicado: (2019)

Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma
por: Shen, Dijian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6qndvvn7kj5b3mehrrg0lef3jq